ArticleCureus2023
A Comparative Cytocompatibility Assessment of Leukocyte-Platelet-Rich Fibrin (L-PRF) and Injectable Platelet-Rich Fibrin (I-PRF) on the Pre-osteoblastic MG-63 Cell Line in Chronic Periodontitis Patients: An In Vitro Study.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim The aim of the study is to assess the cellular viability of various concentrations of different platelet concentrates on pre-osteoblastic MG-63 cells. Materials and methods In this in-vitro experiment, blood samples from 21 individuals with chronic periodontitis were taken and centrifuged according to Choukroun and Miron's protocol to prepare L-PRF and I-PRF, respectively. The methyl thiazolyl tetrazolium (MTT) test was used to determine the viability of 0%, 1%, 2%, 4%, 8%, 10%, and 20% concentrations of L-PRF and I-PRF on MG-63 cells. Results The 20% L-PRF had the lowest percentage of cell viability (90.429±2.06), and the 1% I-PRF had the highest percentage (98.918±0.54), with no statistically significant difference (p>0.05). Conclusion According to the findings of the current study, both L-PRF and I-PRF provide favorable outcomes in terms of the viability of MG-63 cells in chronic periodontitis patients that may be utilized for regenerative purposes such as periodontal osseous defects and mucogingival surgeries. Incorporating these platelet concentrates with bone grafts results in enhanced regenerative outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.